British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis—Executive summary.
- Resource Type
- Article
- Authors
- Holroyd, Christopher R; Seth, Rakhi; Bukhari, Marwan; Malaviya, Anshuman; Holmes, Claire; Curtis, Elizabeth; Chan, Christopher; Yusuf, Mohammed A; Litwic, Anna; Smolen, Susan; Topliffe, Joanne; Bennett, Sarah; Humphreys, Jennifer; Green, Muriel; Ledingham, Jo
- Source
- Rheumatology. Feb2019, Vol. 58 Issue 2, p220-226. 7p.
- Subject
- *BIOTHERAPY
*HEART disease risk factors
*HEPATITIS B
*HEPATITIS C risk factors
*HIV infection risk factors
*THERAPEUTIC use of monoclonal antibodies
*RESPIRATORY disease risk factors
*UVEITIS
*RITUXIMAB
*DIVERTICULOSIS
*RHEUMATOLOGY
*DEMYELINATION
*ADALIMUMAB
*TOCILIZUMAB
*ANTIRHEUMATIC agents
*MEDICAL protocols
*MYCOBACTERIUM tuberculosis
*PATIENT education
*RHEUMATOID arthritis
*DECISION making in clinical medicine
*TUMOR necrosis factors
*COMORBIDITY
*TREATMENT effectiveness
*CHEMICAL inhibitors
*DISEASE risk factors
*THERAPEUTICS
*SOCIETIES
- Language
- ISSN
- 1462-0324
The article presents the executive summary of the biologic disease-modifying antirheumatic drug safety guidelines in inflammatory arthritis by the British Society for Rheumatology. Biologics covered by the guideline are mentioned, including certolizumab pegol. The target audience is secondary care health professionals directly involved in the management of patients with inflammatory arthritis. The GRADE method was used to evaluate the quality of evidence and the strength of recommendation.